Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | SNCA | P37840 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16435130 | 0.85 | PTPN1 (0.51) | TRPV1PTPN1PTGS1PDE4ASNCA | |
| SCHEMBL9356354 | 0.83 | PTPN1 (0.51) | TRPV1PTPN1PTGS1PDE4ASNCA | |
| SCHEMBL9356348 | 0.83 | PTPN1 (0.51) | TRPV1PTPN1PTGS1PDE4ASNCA | |
| SCHEMBL9356482 | 0.81 | TRPV1 (0.54) | TRPV1PTPN1PTGS1PDE4ASNCA | |
| SCHEMBL9356487 | 0.81 | TRPV1 (0.54) | TRPV1PTPN1PTGS1PDE4ASNCA | |
| SCHEMBL3272236 | 0.81 | TRPV1 (0.47) | TRPV1PTPN1PTGS1PDE4ASNCA | |
| SCHEMBL10518145 | 0.79 | PTPN1 (0.50) | TRPV1PTPN1PTGS1PDE4ASNCA | |
| SCHEMBL9356664 | 0.77 | PTPN1 (0.51) | TRPV1PTPN1PTGS1PDE4ASNCA | |
| SCHEMBL9356897 | 0.77 | PTPN1 (0.51) | TRPV1PTPN1PTGS1PDE4ASNCA | |
| SCHEMBL9356928 | 0.77 | PTPN1 (0.51) | TRPV1PTPN1PTGS1PDE4ASNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030182679-A1 | Reducing homogentisate degradation by reducing the activity of homogentisate 1,2-dioxygenase (HGD), maleyl-acetoacetate isomerase(MAAI) and/or fumaryl acetoacetate hydrolase(FAAH) activity | SUNGENE GMBH & CO. KGAA (DE) | 2003-09-25 | — | — | US | disclosed |
| EP-1326994-A2 | IMPROVED METHOD FOR THE BIOSYNTHESIS OF VITAMIN E | Sungene GmbH & Co. KgAA (DE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2001012827-A9 | METHOD FOR PRODUCTION OF TRANSGENIC PLANTS WITH INCREASED TOCOPHEROL CONTENT | SUNGENE GMBH & CO KGAA (DE) | 2002-05-10 | — | — | WO | disclosed |
| EP-1200598-A2 | METHOD FOR PRODUCTION OF TRANSGENIC PLANTS WITH INCREASED TOCOPHEROL CONTENT | Sungene GmbH & Co. KGaA (DE) | 2002-05-02 | — | — | EP | disclosed |
| WO-2002031173-A2 | IMPROVED METHOD FOR THE BIOSYNTHESIS OF VITAMIN E | SUNGENE GMBH & CO. KGAA (DE) | 2002-04-18 | — | — | WO | disclosed |
| WO-2001012827-A2 | METHOD FOR PRODUCTION OF TRANSGENIC PLANTS WITH INCREASED TOCOPHEROL CONTENT | SUNGENE GMBH & CO. KGAA (DE) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030182679-A1 | Reducing homogentisate degradation by reducing the activity of homogentisate 1,2-dioxygenase (HGD), maleyl-acetoacetate isomerase(MAAI) and/or fumaryl acetoacetate hydrolase(FAAH) activity | FAH, GCDH, FH | TRPV1 3531/4885PTPN1 4801/4885PTGS1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.